Introduction of therapeutic reference pricing in Slovenia and its economic consequences

[1]  Bala Iyer.  HERFINDAHL-HIRSCHMAN INDEX (HHI), VALUE CO-CREATORS AND COMPETITIVENESS OF THE INDUSTRY IN INDIA , 2017 .

[2]  Mitja Kos,et al.  Patients’ knowledge and attitude towards therapeutic reference pricing system in Slovenia , 2016, International Journal of Clinical Pharmacy.

[3]  S. Spiridon,et al.  The management of external marketing communication instruments in health care services , 2016, Journal of Medicine and Life.

[4]  Kurt R. Brekke,et al.  Reference Pricing , Generic Entry , and Pharmaceutical Prices , 2015 .

[5]  D. Ross-Degnan,et al.  Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses , 2014, International Journal for Equity in Health.

[6]  P. Shankar,et al.  Essential medicines and health products information portal , 2014, Journal of pharmacology & pharmacotherapeutics.

[7]  W. Cullen,et al.  Patient Perceptions of Generic Medicines: A Mixed-Methods Study , 2014, The Patient - Patient-Centered Outcomes Research.

[8]  L. Wallace,et al.  Family Physicians Provide Feedback On Electronic Health Records In FPM’S User Satisfaction Survey , 2013, The Annals of Family Medicine.

[9]  M. Barry,et al.  A reference pricing system for Ireland , 2012, Expert review of pharmacoeconomics & outcomes research.

[10]  Pieter Dylst,et al.  Reference pricing systems in Europe: characteristics and consequences , 2012 .

[11]  Z. Kaló,et al.  Pitfalls associated with the therapeutic reference pricing practice of asthma medication , 2012, BMC Pulmonary Medicine.

[12]  M. Miraldo,et al.  Effects of Reference Pricing in Pharmaceutical Markets , 2012, PharmacoEconomics.

[13]  Sebastian Schneeweiss,et al.  European Healthcare Policies for Controlling Drug Expenditure , 2012, PharmacoEconomics.

[14]  C. Quintal,et al.  Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. , 2012, Health policy.

[15]  S. Simoens,et al.  The impact of reference-pricing systems in Europe: a literature review and case studies , 2011, Expert review of pharmacoeconomics & outcomes research.

[16]  P. Kanavos,et al.  The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors , 2011, Health economics review.

[17]  T. Stargardt.  The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany , 2010, The European Journal of Health Economics.

[18]  Lt,et al.  Population Number and Age Structure of Marco Polo Sheep in China , 2009 .

[19]  Elizabeth Docteur,et al.  Pharmaceutical pricing policies in a global market , 2008 .

[20]  N. Muszbek,et al.  Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. , 2007, Health policy.

[21]  Kurt R. Brekke,et al.  Reference Pricing of Pharmaceuticals , 2006, Journal of health economics.

[22]  Sajjad Ahmad,et al.  Limiting youth access to tobacco: comparing the long-term health impacts of increasing cigarette excise taxes and raising the legal smoking age to 21 in the United States. , 2007, Health policy.

[23]  M. Kochen,et al.  What do primary care patients think about generic drugs? , 2005, International journal of clinical pharmacology and therapeutics.

[24]  A K Wagner,et al.  Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.

[25]  A. F. Henry,et al.  DEFINITION AND GENERAL CONSIDERATIONS CONCERNING LARGE CHANGES IN REACTIVITY , 1966 .